Purpose; To evaluate the efficacy and safety of the docetaxelcisplatin combination in patients with advanced non-small-cell lung cancer (NSCLC).
Introduction
Docetaxel is a semi-synthetic taxoid derived from 10-deacetyl bacatin III [1] which promotes the assembly of microtubules and inhibits the depolymerization of tubulin, leading to microtubule stabilization [2] . The drug is active in both chemotherapy-naive and previously treated patients with NSCLC, achieving 23%-33% and 21% objective responses, respectively [3] [4] [5] [6] .
Cisplatin is also active in NSCLC, with a mechanism of action different from that of docetaxel. Recent studies showed cisplatin-based chemotherapy in NSCLC to be superior in terms of response rate and survival to regimens containing no cisplatin [7] , and that the use of cisplatin is an independent predictor of improved survival [8] .
Based on antitumor activity against NSCLC and the different mechanisms of action of docetaxel and cisplatin, as well as on preclinical data demonstrating that the two drugs can be efficiently combined [9] , we initiated a multicenter phase II trial in order to evaluate the tolerance and efficacy of their combination.
Docetaxel is a semi-synthetic taxoid derived from lO-deacetyl bacatin III [I] which promotes the assembly of microtubules and inhibits the depolymerization of tubulin, leading to microtubule stabilization [2] . The drug is active in both chemotherapy-naive and previously treated patients with NSCLC, achieving 230/0-33% and 21 % objective responses, respectively [3] [4] [5] [6] .
Based on antitumor activity against NSCLC and the different mechanisms of action of docetaxel and cisplatin, as well as on preclinical data demonstrating that the in patients with stages IIIB and IV disease (P = NS). The median time to progression was 36 weeks and the median survival 48 weeks; the one-year survival was 48%. Grade 3-4 neutropenia occurred in 23 patients, 15 of whom were hospitalized for neutropenic fever; two patients died of sepsis. Grade 2 neurotoxicity was observed in six patients and grade 3 in five patients; grade 3 fatigue occurred in seven patients, grade 3-4 mucositis in four patients and grade 3-4 diarrhea in six patients. Mild allergic reactions and oedema were observed in five and four patients, respectively. The median dose intensity was 30 mg/m2/week for docetaxel and 24 mg/m2/week for cisplatin, corresponding to 91 % and 89% of the specified protocol doses, respectively.
Conclusions: The docetaxel-cisplatin combination is an active regimen in advanced NSCLC, but hematologic toxicity remains high despite the prophylactic use of G-CSF.
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Patients and methods

Patients and staging
Chemotherapy-naive patients (age < 75 years) with bidimensionally measurable stage IIIBIIV NSCLC were enrolled. Prior irradiation of brain metastases was allowed provided that the brain lesions were radiologically stable or improved. Other inclusion criteria were: World Health Organization (WHO) performance status 0-2; absolute granulocyte count (AGC) > 1500/dl and platelet count > 120.000/dl; normal renal (serum creatinine < I mg/dl), liver (serum bilirubin < 1.5 mg/dl) and cardiac function. Patients with a second primary (except non-melanomatous skin cancer or in situ cervical cancer), severe infection or malnutrition were excluded. Informed consent was obtained from all patients.
Patient evaluation
Pretreatment evaluation included a complete medical history and physical examination, a complete blood count (CBC) with differential and platelet counts, a standard biochemical profile, electrocardiogram (ECG), chest X-rays, computed tomography (CT) scans of the chest, abdomen and brain, and a whole bone scan. CBC counts were performed weekly or daily in instances of > grade 2 myelosuppression. Motor and sensory velocity measurements and vibration tests were performed in instances of grade 4 neurotoxicity. Lesions assessable by physical examination and chest X-rays were evaluated before each cycle whilst those assessable by ultrasound and CTscan were measured after three courses.
Treatment
Docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) was administered on day 1 at a dose of 100 mg/m 2 over a one-hour infusion; premedication with dexamethasone was routinely given. Cisplatin (CDDP; Platinol, Bristol-Myers Squibb Co.. Princeton NJ, USA) was administreted on day 2 at a dose of 80 mg/m 2 after adequate hydration. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; Granocyte, Rhone Poulenc Rorer; 150 ug/m 2 subcutaneously) was given from day 3 to day 13 post-treatment or until the AGC (absolute granulocyte count) was at least 1200/dl on two consecutive occasions after the nadir. Treatment was repeated every three weeks and was continued until there was evidence of disease progression or the occurrence of intolerable toxicity, except for neutropenia, which precluded further treatment.
Dose adjustment criteria were as follows: both drugs were reduced by 20% in instances of grade 4 neutropenia or thrombocytopenia lasting more than five days or febrile neutropenia; in instances of grade 3-4 neurotoxicity and fatigue, treatment was delayed for one to two weeks and both drugs were reduced by 25% and 20%, respectively. WHO toxicity and response criteria were applied [10] .
Statistical methods
Duration of response was calculated from the day that the complete response (CR) or partial response (PR) criteria were first met until the day of documented clinical disease progression. The time to disease progression (TTP) and overall survival were calculated from initiation of chemotherapy using the Kaplan-Meier method. The x 2 -lest was used for comparison analysis.
Results
Patient population
Fifty-three patients (Table 1 ) entered the study from May 1995 to September 1996 and all were evaluable for response and toxicity. Three patients refused further treatment after the first course because of myelotoxicity.
Response to treatment and survival
There were 24 objective responses (one CR, 1.9%; 23 PRs, 43.4%), for an overall response rate (OR) of 45.2% (95% CI: 31.9%-58.7%). Nine patients (17%) had SD and 17 (32%) PD. The response rate was not statistically different according to histology, weight loss, performance status or disease stage. Responses were observed in lung (47%), lymph nodes (69%) and liver (80%). The median duration of response was 24 weeks (range 4-56) and the median TTP 34 weeks (range 8-68). After a median follow-up of 48 weeks (range 4-122), 21 patients (40%) remain alive; the median overall survival was 58 weeks (range 4-122) and the one-year survival 48%. There was no difference in the duration of response, the TTP or the overall survival according to disease stage.
Compliance with treatment and toxicity
Two hundred twenty-three courses (median four courses/ patient; range 1-11) were administered with a median interval between courses of 21 days (range 21-31). Thirtysix courses (16%), corresponding to 20 patients, were delayed for the following reasons: febrile neutropenia (« = 3), other hematologic toxicities (n -3), non-neutropenic infection (n -2), neurotoxicity and fatigue (n -9), acute myocardial ischemia (/; = 1), pericardial effusion (n -1), acute renal failure (n -1), bleeding of the upper gastrointestinal tract (n -1) and for other reasons unrelated to the treatment (/; = 15). Three patients refused treatment because of hematologic toxicity. Twenty patients (38%) were withdrawn from the study because of disease progression. Five responding patients (9%) discontinued treatment after they had received six to nine courses, and 17 patients (32%) (14 PRs and three SDs) received ^ six courses (range 6-11). Fourteen (26%) and seven (13%) patients received reduced doses because of grade 4 neutropenia and grade 3 fatigue, respectively. The median dose intensity was 30 mg/m 2 /week for docetaxel and 24 mg/m 2 /week for CDDP, corresponding to 91% and 89% of the planned doses, respectively. Grade 3-4 neutropenia occurred in 23 patients (43%. Pretreatment evaluation included a complete medical history and physical examination, a complete blood count (CBC) with differential and platelet counts, a standard biochemical profile, electrocardiogram (ECG), chest X-rays, computed tomography (CT) scans of the chest. abdomen and brain, and a whole bone scan. CBC counts were performed weekly or daily in instances of > grade 2 myelosuppression. Motor and sensory velocity measurements and vibration tests were performed in instances of grade 4 neurotoxicity. Lesions assessable by physical examination and chest X-rays were evaluated before each cycle whilst those assessable by ultrasound and CT scan were measured after three courses. Treatment Docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) was administered on day I at a dose of 100 mg/m 2 over a one-hour infusIOn; premedication with dexamethasone was routinely given. Cisplatin (COOP; Platinol, Bristol-Myers Squibb Co., Princeton NJ, USA) was administreted on day 2 at a dose of 80 mg/m 2 after adequate hydratIOn. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; Granocyte, Rhone Poulenc Rorer; 150 ~g/m2 subcutaneously) was given from day 3 to day 13 post-treatment or until the AGC (absolute granulocyte count) was at least 1200/dl on two consecutive occaSIOns after the nadir. Treatment was repeated every three weeks and was continued until there was evidence of disease progression or the occurrence of Intolerable toxicity, except for neutropenia, which precluded further treatment.
Dose adjustment critena were as follows: both drugs were reduced by 20% in instances of grade 4 neutropenia or thrombocytopenia lastIng more than five days or febrile neutropenia; in Instances of grade 3-4 neurotoxicity and fatigue, treatment was delayed for one to two weeks and both drugs were reduced by 25% and 20%, respectively. WHO toxicity and response criteria were applied [10] .
Statistical methods
Duration of response was calculated from the day that the complete response (CR) or partial response (PR) criteria were first met until the day of documented clinical disease progression. The time to disease progression (TIP) and overall survival were calculated from initiatIon of chemotherapy using the Kaplan-Meier method. The x2-test was used for comparison analYSIS.
Results
Patient population
Fifty-three patients (Table I ) entered the study from May 1995 to September 1996 and all were evaluable for response and toxicity. Three patients refused further treatment after the first course because of myelotoxicity.
Response to treatment and survival
There were 24 objective responses (one CR, 1.9%; 23 PRs, 43.4%), for an overall response rate (OR) of 45.2% (95% CI: 31.90/0-58.7%). Nine patients (17%) had SO and 17 (32%) PD. The response rate was not statistically different according to histology, weight loss, performance status or disease stage. Responses were observed in lung (47%), lymph nodes (69%) and liver (80%). The median duration of response was 24 weeks (range 4-56) and the median TTP 34 weeks (range 8-68). After a median follow-up of 48 weeks (range 4-122), 21 patients (40%) remain alive; the median overall survival was 58 weeks (range 4-122) and the one-year survival 48%. There was no difference in the duration of response, the TTP or the overall survival according to disease stage.
Compliance \Vith treatment and toxicity
Two hundred twenty-three courses (median four courses/ patient; range I-II) were administered with a median interval between courses of 21 days (range 21-31). Thirtysix courses (16%), corresponding to 20 patients, were delayed for the following reasons: febrile neutropenia (n = 3), other hematologic toxicities (11 = 3), non-neutropenic infection (n = 2), neurotoxicity and fatigue (11 = 9), acute myocardial ischemia (n = 1), pericardial effusion (11 = I), acute renal failure (n = I), bleeding of the upper gastrointestinal tract (n = 1) and for other reasons unrelated to the treatment (11 = 15). Three patients refused treatment because of hematologic toxicity. Twenty patients (38%) were withdrawn from the study because of disease progression. Five responding patients (9%) discontinued treatment after they had received six to nine courses, and 17 patients (32%) (14 PRs and three SOs) received ~ six courses (range 6-11). Fourteen (26%) and seven (13%) patients received reduced doses because of grade 4 neutropenia and grade 3 fatigue, respectively. The median dose intensity was 30 mg/m2/week for docetaxel and 24 mg/m2/week for COOP, corresponding to 91 % and 89% of the planned doses, respectively. Grade 3-4 neutropenia occurred in 23 patients (43%. Table 2 ). Sixty-five percent of the neutropenic episodes (median duration two days, range 2-6) were observed between days 6 and 10 post-treatment. Fifteen patients (28%) were hospitalized for neutropenic fever, (median duration four days; range 2-8) and two of them died of sepsis. Grade 3-4 thrombocytopenia and anemia occurred in three patients (6%) each. Anemia seems to be cumulative. Non-hematologic toxicity (Table 2) included grade 3 nausea and vomiting (n = 3), grade 3-4 mucositis, (n = 4), grade 3-4 diarrhea (n = 6), grade 2-3 neurotoxicity (n = 11) and grade 2-3 fatigue (n = 11).
Discussion
The efficacy results (OR 45%, and one-year survival 48%) of this trial clearly indicate that the docetaxelcisplatin combination is an effective regimen in advanced NSCLC; the regimen was particularly active in liver and lymph node metastases. Although a subgroup of study patients had stage IIIB disease which could influence both response rates and survival, the statistical analysis failed to demonstrate significant differences in the efficacy of the treatment according to disease stage. The toxicity of the docetaxel-cisplatin regimen was significant, since grade 4 neutropenia and neutropenic fever requiring hospitalization occurred in 26% and 28% of the patients, respectively; in addition, two patients 333 died of sepsis. Phase I studies have also shown that the dose-limiting toxicity of this combination is neutropenia and the recommended doses for phase II studies ranged from 75 mg/m 2 to 100 mg/m 2 for each drug [11] [12] [13] . Preliminary results from two docetaxel-cisplatin phase II studies initiated in Australia and France have also demonstrated that febrile neutropenia developed in 13%-15% of the patients despite differences in the schedules and doses used [14] . Viallet et al. [15] , using an alternate schedule of administration of docetaxel, cisplatin and vinorelbine in a six-week cycle, observed a high incidence of grade 3-4 neutopenia but only four episodes of febrile neutropenia. In the present study, rhG-CSF failed to prevent the development of severe neutropenia, which was, however, of short duration. The high incidence of neutropenia and febrile neutropenia as well as the observed toxic deaths was not acceptable in patients with an incurable and fatal disease. In addition, the use of rhG-CSF has an important impact on the economic cost of the regimen. The use of lower doses of docetaxel, which is the most myelotoxic drug of the combination, may result in fewer infectious episodes [14] and thereby limit the economic cost. In the present study docetaxel was given at a dose of 100 mg/m 2 which yielded a one-year survival of 48%; however, in other phase II studies [14] docetaxel was administered at a dose of 75 mg/m 2 and the observed one-year survival was less than 40%. Whether dose intensity for docetaxel results in more objective responses and improved survival is not yet clear and needs to be addressed in a separate study; only then might higher toxicity and economic cost perhaps be justified.
Finally, the low incidence of neurotoxicity despite the neurotoxicity of both drugs is of interest. Similar results have also been reported by Berille [14] . In contrast, fatigue was a more serious problem in our study since it was a major reason for treatment delays and dose reductions. It is also interesting that some patients experienced grade 2 fatigue after the first or the second cycle, suggesting that this adverse effect is not always cumulative and that unknown biochemical mechanisms may be responsible.
